Developing bivalent ligands to target CUG triplet repeats, the causative agent of myotonic dystrophy type 1

Journal of Medicinal Chemistry

Volumn 56, Issue 23, 2013, Pages 9471-9481

  Jahromi, Amin Haghighat ^a,b   Fu, Yuan ^b,c   Miller, Kali A ^b   Nguyen, Lien ^b   Luu, Long M ^b   Baranger, Anne M ^b,d   Zimmerman, Steven C ^a,b  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c Department of Obstetrics Gynecology   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIGAND; RNA;

ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; BIOSENSOR; CELL NUCLEUS; CONTROLLED STUDY; FLUORESCENCE MICROSCOPY; MYOTONIC DYSTROPHY; SYNTHESIS;

EID: 84890468828     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400794z     Document Type: Article

References (70)

1. Foff, E. P.; Mahadevan, M. S. Therapeutics development in myotonic dystrophy type 1 Muscle Nerve 2011, 44, 160-169
2. Kanadia, R. N.; Johnstone, K. A.; Mankodi, A.; Lungu, C.; Thornton, C. A.; Esson, D.; Timmers, A. M.; Hauswirth, W. W.; Swanson, M. S. A muscleblind knockout model for myotonic dystrophy Science 2003, 302, 1978-1980
3. Mooers, B. H. M.; Logue, J. S.; Berglund, J. A. The structural basis of myotonic dystrophy from the crystal structure of CUG repeats Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 16626-16631
4. Kiliszek, A.; Kierzek, R.; Krzyzosiak, W. J.; Rypniewski, W. Structural insights into CUG repeats containing the 'stretched U-U wobble': Implications for myotonic dystrophy Nucleic Acids Res. 2009, 37, 4149-4156
5. Grammatikakis, I.; Goo, Y. H.; Echeverria, G. V.; Cooper, T. A. Identification of MBNL1 and MBNL3 domains required for splicing activation and repression Nucleic Acids Res. 2011, 39, 2769-2780
6. Kanadia, R. N.; Shin, J.; Yuan, Y.; Beattie, S. G.; Wheeler, T. M.; Thornton, C. A.; Swanson, M. S. Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 11748-11753
7. O'Rourke, J. R.; Swanson, M. S. Mechanisms of RNA-mediated disease J. Biol. Chem. 2009, 284, 7419-7423
8. Mulders, S. A.; van Engelen, B. G.; Wieringa, B.; Wansink, D. G. Molecular therapy in myotonic dystrophy: Focus on RNA gain-of-function Hum. Mol. Genet. 2010, 19, R90-97
9. Lee, J. E.; Cooper, T. A. Pathogenic mechanisms of myotonic dystrophy Biochem. Soc. Trans. 2009, 37, 1281-1286
10. Cooper, T. A. A reversal of misfortune for myotonic dystrophy? New Engl. J. Med. 2006, 355, 1825-1827
11. Ward, A. J.; Rimer, M.; Killian, J. M.; Dowling, J. J.; Cooper, T. A. CUGBP1 overexpression in mouse skeletal muscle reproduces features of myotonic dystrophy type 1 Hum. Mol. Genet. 2010, 19, 3614-3622
12. Zhang, L.; Lee, J. E.; Wilusz, J.; Wilusz, C. J. The RNA-binding protein CUGBP1 regulates stability of tumor necrosis factor mRNA in muscle cells: Implications for myotonic dystrophy J. Biol. Chem. 2008, 283, 22457-22463
13. Kuyumcu-Martinez, N. M.; Wang, G. S.; Cooper, T. A. Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation Mol. Cell 2007, 28, 68-78
14. Jones, K.; Jin, B.; Iakova, P.; Huichalaf, C.; Sarkar, P.; Schneider-Gold, C.; Schoser, B.; Meola, G.; Shyu, A. B.; Timchenko, N.; Timchenko, L. RNA Foci, CUGBP1, and ZNF9 are the primary targets of the mutant CUG and CCUG repeats expanded in myotonic dystrophies type 1 and type 2 Am. J. Pathol. 2011, 179, 2475-2489
15. Wheeler, T. M.; Leger, A. J.; Pandey, S. K.; MacLeod, A. R.; Nakamori, M.; Cheng, S. H.; Wentworth, B. M.; Bennett, C. F.; Thornton, C. A. Targeting nuclear RNA for in vivo correction of myotonic dystrophy Nature 2012, 488, 111-115
16. Cooper, T. a. Chemical reversal of the RNA gain of function in myotonic dystrophy Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 18433-18434
17. Lee, J. E.; Bennett, C. F.; Cooper, T. A. RNase H-mediated degradation of toxic RNA in myotonic dystrophy type 1 Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 4221-4226
18. Sobczak, K.; Wheeler, T. M.; Wang, W.; Thornton, C. A. RNA interference targeting CUG repeats in a mouse model of myotonic dystrophy Mol. Ther. 2013, 21, 380-387
19. Wheeler, T. M.; Sobczak, K.; Lueck, J. D.; Osborne, R. J.; Lin, X.; Dirksen, R. T.; Thornton, C. A. Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA Science 2009, 325, 336-339
20. García-López, A.; Llamusí, B.; Orzáez, M.; Pérez-Payá, E.; Artero, R. D. In vivo discovery of a peptide that prevents CUG-RNA hairpin formation and reverses RNA toxicity in myotonic dystrophy models Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 11866-11871
21. Warf, M. B.; Nakamori, M.; Matthys, C. M.; Thornton, C. A.; Berglund, J. A. Pentamidine reverses the splicing defects associated with myotonic dystrophy Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 18551-18556
22. Ofori, L. O.; Hoskins, J.; Nakamori, M.; Thornton, C. A.; Miller, B. L. From dynamic combinatorial 'hit' to lead: In vitro and in vivo activity of compounds targeting the pathogenic RNAs that cause myotonic dystrophy Nucleic Acids Res. 2012, 40, 6380-6390
23. Parkesh, R.; Childs-Disney, J. L.; Nakamori, M.; Kumar, A.; Wang, E.; Wang, T.; Hoskins, J.; Tran, T.; Housman, D.; Thornton, C. A.; Disney, M. D. Design of a bioactive small molecule that targets the myotonic dystrophy type 1 RNA via an RNA motif-ligand database and chemical similarity searching J. Am. Chem. Soc. 2012, 134, 4731-4742
24. Pushechnikov, A.; Lee, M. M.; Childs-Disney, J. L.; Sobczak, K.; French, J. M.; Thornton, C. A.; Disney, M. D. Rational design of ligands targeting triplet repeating transcripts that cause RNA dominant disease: Application to myotonic muscular dystrophy type 1 and spinocerebellar ataxia type 3 J. Am. Chem. Soc. 2009, 131, 9767-9779
25. Childs-Disney, J. L.; Hoskins, J.; Rzuczek, S. G.; Thornton, C. A.; Disney, M. D. Rationally designed small molecules targeting the RNA that causes myotonic dystrophy type 1 are potently bioactive ACS Chem. Biol. 2012, 7, 856-862
26. Arambula, J. F.; Ramisetty, S. R.; Baranger, A. M.; Zimmerman, S. C. A simple ligand that selectively targets CUG trinucleotide repeats and inhibits MBNL protein binding Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 16068-16073
27. (exp)·MBNL1 inhibitor with therapeutic potential for myotonic dystrophy type 1 ACS Chem. Biol. 2013, 8, 1037-1043
28. Krishnamurthy, V. M.; Estroff, L. A.; Whitesides, G. M. Multivalency in ligand design. In Fragment-Based Approaches in Drug Discovery; Jahnke, W.; Erlanson, D. A., Eds.; Wiley-VCH: Weinheim, Germany, 2006.
29. Mammen, M.; Choi, S. K.; Whitesides, G. M. Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors Angew. Chem., Int. Ed. 1998, 37, 2755-2794
30. Lees, W. J.; Spaltenstein, A.; Kingery-Wood, J. E.; Whitesides, G. M. Polyacrylamides bearing pendant alpha-sialoside groups strongly inhibit agglutination of erythrocytes by influenza A virus: multivalency and steric stabilization of particulate biological systems J. Med. Chem. 1994, 37, 3419-3433
31. Jervis, P. J.; Moulis, M.; Jukes, J. P.; Ghadbane, H.; Cox, L. R.; Cerundolo, V.; Besra, G. S. Towards multivalent CD1d ligands: Synthesis and biological activity of homodimeric alpha-galactosyl ceramide analogues Carbohydr. Res. 2012, 356, 152-162
32. Sucheck, S. J.; Wong, A. L.; Koeller, K. M.; Boehr, D. D.; Draker, K.-a.; Sears, P.; Wright, G. D.; Wong, C.-H. Design of bifunctional antibiotics that target bacterial rRNA and inhibit resistance-causing enzymes J. Am. Chem. Soc. 2000, 122, 5230-5231
33. Tamiz, A. P.; Zhang, J.; Zhang, M.; Wang, C. Z.; Johnson, K. M.; Kozikowski, A. P. Application of the bivalent ligand approach to the design of novel dimeric serotonin reuptake inhibitors J. Am. Chem. Soc. 2000, 122, 5393-5394
34. Gestwicki, J. E.; Cairo, C. W.; Strong, L. E.; Oetjen, K. a.; Kiessling, L. L. Influencing receptor-ligand binding mechanisms with multivalent ligand architecture J. Am. Chem. Soc. 2002, 124, 14922-14933
35. Agnelli, F.; Sucheck, S. J.; Marby, K. A.; Rabuka, D.; Yao, S. L.; Sears, P. S.; Liang, F. S.; Wong, C. H. Dimeric aminoglycosides as antibiotics Angew. Chem., Int. Ed. 2004, 43, 1562-1566
36. Lee, M. M.; Pushechnikov, A.; Disney, M. D. Rational and modular design of potent ligands targeting the RNA that causes myotonic dystrophy 2 ACS Chem. Biol. 2009, 4, 345-355
37. Childs-Disney, J. L.; Tsitovich, P. B.; Disney, M. D. Using modularly assembled ligands to bind RNA internal loops separated by different distances ChemBioChem 2011, 12, 2143-2146
38. Shonberg, J.; Scammells, P. J.; Capuano, B. Design strategies for bivalent ligands targeting GPCRs ChemMedChem 2011, 6, 963-974
39. Kitov, P. I.; Bundle, D. R. On the nature of the multivalency effect: A thermodynamic model J. Am. Chem. Soc. 2003, 125, 16271-16284
40. Zhang, Y.; Gilliam, A.; Maitra, R.; Damaj, M. I.; Tajuba, J. M.; Seltzman, H. H.; Thomas, B. F. Synthesis and biological evaluation of bivalent ligands for the cannabinoid 1 receptor J. Med. Chem. 2010, 53, 7048-7060
41. Birnkammer, T.; Spickenreither, A.; Brunskole, I.; Lopuch, M.; Kagermeier, N.; Bernhardt, G.; Dove, S.; Seifert, R.; Elz, S.; Buschauer, A. The bivalent ligand approach leads to highly potent and selective acylguanidine-type histamine H(2) receptor agonists J. Med. Chem. 2012, 55, 1147-1160
42. Kühhorn, J.; Götz, A.; Hübner, H.; Thompson, D.; Whistler, J.; Gmeiner, P. Development of a bivalent dopamine D(2) receptor agonist J. Med. Chem. 2011, 54, 7911-7919
43. Kühhorn, J.; Hübner, H.; Gmeiner, P. Bivalent dopamine D2 receptor ligands: Synthesis and binding properties J. Med. Chem. 2011, 54, 4896-4903
44. Peng, Y.; Sun, H.; Lu, J.; Liu, L.; Cai, Q.; Shen, R.; Yang, C. Y.; Yi, H.; Wang, S. Bivalent Smac mimetics with a diazabicyclic core as highly potent antagonists of XIAP and cIAP1/2 and novel anticancer agents J. Med. Chem. 2012, 55, 106-114
45. Liu, J.; Brahimi, F.; Saragovi, H. U.; Burgess, K. Bivalent diketopiperazine-based tropomysin receptor kinase C (TrkC) antagonists J. Med. Chem. 2010, 53, 5044-5048
46. Haghighat Jahromi, A.; Honda, M.; Zimmerman, S. C.; Spies, M. Single-molecule study of the CUG repeat-MBNL1 interaction and its inhibition by small molecules Nucleic Acids Res. 2013, 41, 6687-6697
47. Wong, C. H.; Richardson, S. L.; Ho, Y. J.; Lucas, A. M.; Tuccinardi, T.; Baranger, A. M.; Zimmerman, S. C. Investigating the binding mode of an inhibitor of the MBNL1·RNA complex in myotonic dystrophy type 1 (DM1) leads to the unexpected discovery of a DNA-selective binder ChemBioChem 2012, 13, 2505-2509
48. Wakelin, L. P. G. Polyfunctional DNA intercalating agents Med. Res. Rev. 1986, 6, 275-340
49. Zimmerman, S. C.; Lamberson, C. R.; Cory, M.; Fairley, T. A. Topologically constrained bifunctional intercalators: DNA intercalation by a macrocyclic bisacridine J. Am. Chem. Soc. 1989, 111, 6805-6809
50. Veal, J. M.; Li, Y.; Zimmerman, S. C.; Lamberson, C. R.; Cory, M.; Zon, G.; Wilson, W. D. Interaction of a macrocyclic bisacridine with DNA Biochemistry 1990, 29, 10918-10927
51. Denny, W. A. Acridine derivatives as chemotherapeutic agents Curr. Med. Chem. 2002, 9, 1655-1665
52. Fechter, E. J.; Olenyuk, B.; Dervan, P. B. Design of a sequence-specific DNA bisintercalator Angew. Chem., Int. Ed. 2004, 43, 3591-3594
53. Goodell, J. R.; Madhok, A. A.; Hiasa, H.; Ferguson, D. M. Synthesis and evaluation of acridine- and acridone-based anti-herpes agents with topoisomerase activity Bioorg. Med. Chem. 2006, 14, 5467-5480
54. Rhoden Smith, A.; Iverson, B. L. Threading polyintercalators with extremely slow dissociation rates and extended DNA binding sites J. Am. Chem. Soc. 2013, 135, 12783-12789
55. Antonini, I.; Polucci, P.; Magnano, A.; Gatto, B.; Palumbo, M.; Menta, E.; Pescalli, N.; Martelli, S. Design, synthesis, and biological properties of new bis(acridine-4-carboxamides) as anticancer agents J. Med. Chem. 2003, 46, 3109-3115
56. Caffrey, C. R.; Steverding, D.; Swenerton, R. K.; Kelly, B.; Walshe, D.; Debnath, A.; Zhou, Y. M.; Doyle, P. S.; Fafarman, A. T.; Zorn, J. A.; Land, K. M.; Beauchene, J.; Schreiber, K.; Moll, H.; Ponte-Sucre, A.; Schirmeister, T.; Saravanamuthu, A.; Fairlamb, A. H.; Cohen, F. E.; McKerrow, J. H.; Weisman, J. L.; May, B. C. Bis-acridines as lead antiparasitic agents: Structure-activity analysis of a discrete compound library in vitro Antimicrob. Agents Chemother. 2007, 51, 2164-2172
57. Bobrovnik, S. A. The influence of rigid or flexible linkage between two ligands on the effective affinity and avidity for reversible interactions with bivalent receptors J. Mol. Recognit. 2007, 20, 253-262
58. Knuf, E. C.; Jiang, J.-K.; Gin, M. S. Preparation of discrete oligoethers: synthesis of pentabutylene glycol and hexapropylene glycol by two complementary methods J. Org. Chem. 2003, 68, 9166-9169
59. Fischer, W.; Brissault, B.; Prévost, S.; Kopaczynska, M.; Andreou, I.; Janosch, A.; Gradzielski, M.; Haag, R. Synthesis of linear polyamines with different amine spacings and their ability to form dsDNA/siRNA complexes suitable for transfection Macromol. Biosci. 2010, 10, 1073-1083
60. Delcros, J. G.; Tomasi, S.; Carrington, S.; Martin, B.; Renault, J.; Blagbrough, I. S.; Uriac, P. Effect of spermine conjugation on the cytotoxicity and cellular transport of acridine J. Med. Chem. 2002, 45, 5098-5111
61. Crothers, D. M. Calculation of binding isotherms for heterogenous polymers Biopolymers 1968, 6, 575-584
62. Laurent, F. X.; Sureau, A.; Klein, A. F.; Trouslard, F.; Gasnier, E.; Furling, D.; Marie, J. New function for the RNA helicase p68/DDX5 as a modifier of MBNL1 activity on expanded CUG repeats Nucleic Acids Res. 2012, 40, 3159-3171
63. Fu, Y.; Ramisetty, S. R.; Hussain, N.; Baranger, A. M. MBNL1-RNA recognition: Contributions of MBNL1 sequence and RNA conformation ChemBioChem 2012, 13, 112-119
64. Alessi, M. L.; Norman, A. I.; Knowlton, S. E.; Ho, D. L.; Greer, S. C. Helical and coil conformations of poly(ethylene glycol) in isobutyric acid and water Macromolecules 2005, 38, 9333-9340
65. Vámosi, G.; Gohlke, C.; Clegg, R. M. Fluorescence characteristics of 5-carboxytetramethylrhodamine linked covalently to the 5′ end of oligonucleotides: Multiple conformers of single-stranded and double-stranded dye-DNA complexes Biophys. J. 1996, 71, 972-994
66. Qu, P.; Chen, X. D.; Zhou, X. X.; Li, X.; Zhao, X. S. Fluorescence quenching of TMR by guanosine in oligonucleotides Sci. China, Ser. B: Chem. 2009, 52, 1653-1659
67. Feng, B. Y.; Shoichet, B. K. A detergent-based assay for the detection of promiscuous inhibitors Nat. Protoc. 2006, 1, 550-553
68. Vichai, V.; Kirtikara, K. Sulforhodamine B colorimetric assay for cytotoxicity screening Nat. Protoc. 2006, 1, 1112-1116
69. Echeverria, G. V.; Cooper, T. A. RNA-binding proteins in microsatellite expansion disorders: mediators of RNA toxicity Brain Res. 2012, 1462, 100-111
70. Ho, T. H.; Savkur, R. S.; Poulos, M. G.; Mancini, M. A.; Swanson, M. S.; Cooper, T. A. Colocalization of muscleblind with RNA foci is separable from mis-regulation of alternative splicing in myotonic dystrophy J. Cell Sci. 2005, 118, 2923-2933